Livforsakringsbolaget Skandia’s BeOne Medicines Ltd ONC Stock Holding History

Livforsakringsbolaget Skandia’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-11,000	Closed	-$3.15M	–	678
2020 Q3	$3.15M	Buy	11,000 +1,500	+16%	+$353K	0.34%	69
2020 Q2	$1.79M	Hold	9,500	–	–	0.2%	104
2020 Q1	$1.17M	Hold	9,500	–	–	0.16%	122
2019 Q4	$1.57M	Hold	9,500	–	–	0.19%	125
2019 Q3	$1.16M	Hold	9,500	–	–	0.14%	146
2019 Q2	$1.18M	Buy	9,500 +1,400	+17%	+$178K	0.14%	142
2019 Q1	$1.07M	Hold	8,100	–	–	0.14%	152
2018 Q4	$1.14M	Buy	+8,100	New	+$1.07M	0.17%	131

Other funds holding ONC

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Livforsakringsbolaget Skandia's ONC Position: Q4 2020 in Review

Livforsakringsbolaget Skandia sold out of BeOne Medicines Ltd (ONC) in Q4 2020, closing a stake of 11,000 shares — an estimated $3.15M sold.

Livforsakringsbolaget Skandia first reported a position in ONC in Q4 2018 and held it in 8 quarters. The position peaked at $3.15M in Q3 2020. 248 funds tracked by Wall St. Rank hold ONC as of Q4 2020.

Livforsakringsbolaget Skandia reported no remaining BeOne Medicines Ltd position as of Q4 2020 after selling out during the quarter.
Livforsakringsbolaget Skandia sold 11,000 BeOne Medicines Ltd shares in Q4 2020, an estimated $3.15M.
Livforsakringsbolaget Skandia first reported a position in BeOne Medicines Ltd in Q4 2018 and held it in 8 quarters.
Livforsakringsbolaget Skandia's BeOne Medicines Ltd position peaked at $3.15M in Q3 2020.
248 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q4 2020.

Based on Livforsakringsbolaget Skandia's 13F filing for Q4 2020, filed 2 Mar 2021.